Jazz Pharmaceuticals plc
JAZZ
$138.81
$2.361.73%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.09B | 1.05B | 1.02B | 901.98M | 1.01B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.09B | 1.05B | 1.02B | 901.98M | 1.01B |
| Cost of Revenue | 90.92M | 111.61M | 109.90M | 66.54M | 74.89M |
| Gross Profit | 997.25M | 943.36M | 913.92M | 835.44M | 937.04M |
| SG&A Expenses | 399.73M | 325.77M | 338.52M | 351.71M | 360.10M |
| Depreciation & Amortization | 158.90M | 157.46M | 155.22M | 155.73M | 151.55M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 859.61M | 794.76M | 824.38M | 796.83M | 777.39M |
| Operating Income | 228.56M | 260.21M | 199.44M | 105.15M | 234.55M |
| Income Before Tax | 133.20M | 200.52M | 137.92M | -2.95M | 61.07M |
| Income Tax Expenses | -57.91M | -14.53M | -30.65M | 11.67M | -33.09M |
| Earnings from Continuing Operations | 191.12M | 215.06M | 168.57M | -14.62M | 94.15M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 191.12M | 215.06M | 168.57M | -14.62M | 94.15M |
| EBIT | 228.56M | 260.21M | 199.44M | 105.15M | 234.55M |
| EBITDA | 396.98M | 425.44M | 362.48M | 268.53M | 393.75M |
| EPS Basic | 3.16 | 3.50 | 2.68 | -0.23 | 1.50 |
| Normalized Basic EPS | 1.77 | 2.04 | 1.37 | 0.36 | 1.73 |
| EPS Diluted | 3.11 | 3.42 | 2.49 | -0.23 | 1.42 |
| Normalized Diluted EPS | 1.74 | 1.98 | 1.24 | 0.36 | 1.55 |
| Average Basic Shares Outstanding | 60.54M | 61.41M | 62.88M | 62.54M | 62.58M |
| Average Diluted Shares Outstanding | 61.50M | 63.17M | 69.63M | 62.54M | 69.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
